Company intelligence / Profile preview

Verastem Oncology

Needham, Massachusetts, United Statesverastem.com ↗

Ownership: Public · VSTM
Employees: ~100
Development stage: Phase 3

Overview

Avutometinib plus defactinib granted priority review by FDA under accelerated approval pathway for recurrent KRAS mutant LGSOC with PDUFA action date set for June 30, 2025. RAMP 205 trial in metastatic pancreatic cancer progressing with data expected in Q1 2025. VS-7375 (KRAS G12D inhibitor) on track for IND filing in Q1 2025.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

11 assets

duvelisib

Approved

10 more assets in the full pipeline.

Request access →

Partnerships

GenFleet Therapeutics (collaboration on three discovery programs including VS-7375)

Beyond the preview

Go deeper on Verastem Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verastem Oncology.

Explore the full profile